We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

55 hedge funds and large institutions have $5.47M invested in Adaptimmune Therapeutics in 2025 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more call options, than puts

Call options by funds: $37K | Put options by funds: $27K

15% less funds holding

Funds holding: 65 → 55 (-10)

27.73% less ownership

Funds ownership: 43.61% → 15.88% (-28%)

42% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 24

42% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 12

80% less capital invested

Capital invested by funds: $27.7M → $5.47M (-$22.2M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
55
Holders Change
-10
Holders Change %
-15.38%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
14
Increased
7
Reduced
12
Closed
24
Calls
$37K
Puts
$27K
Net Calls
+$10K
Net Calls Change
-$1K

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$906K
2
Jane Street
Jane Street
New York
+$385K
3
Renaissance Technologies
Renaissance Technologies
New York
+$298K
4
BRWA
B. Riley Wealth Advisors
Florida
+$68.6K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$36.5K

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$6.57M
2
TSC
Two Seas Capital
New York
-$5.41M
3
NMC
NEA Management Company
Maryland
-$4.09M
4
MAM
MPM Asset Management
Massachusetts
-$1.15M
5
MB
MPM BioImpact
Massachusetts
-$1.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
CAP
26
Columbia Advisory Partners
Washington
$4.78K – – –
SG Americas Securities
27
SG Americas Securities
New York
$4K +$3.77K +27,497 New
SQA
28
Simon Quick Advisors
New Jersey
$3.9K – – –
Raymond James Financial
29
Raymond James Financial
Florida
$3.28K – – –
PWM
30
Prosperity Wealth Management
California
$2.5K -$74 -536 -3%
SG
31
StoneX Group
New York
$1.96K +$2.06K +15,040 New
TCM
32
Traynor Capital Management
Pennsylvania
$1.95K +$2.06K +15,000 New
Goldman Sachs
33
Goldman Sachs
New York
$1.6K +$1.69K +12,320 New
Rockefeller Capital Management
34
Rockefeller Capital Management
New York
$1.58K +$1.67K +12,166 New
IA
35
IFG Advisory
Georgia
$1.52K – – –
KCM
36
Kornitzer Capital Management
Kansas
$1.3K – – –
XSC
37
X-Square Capital
Puerto Rico
$1K +$55 +400 +4%
Simplex Trading
38
Simplex Trading
Illinois
$1K +$1.71K +12,424 New
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$745 -$383 -2,790 -33%
Wells Fargo
40
Wells Fargo
California
$351 -$6.34K -46,200 -94%
Citigroup
41
Citigroup
New York
$348 +$368 +2,679 New
Barclays
42
Barclays
United Kingdom
$330 – – –
Osaic Holdings
43
Osaic Holdings
Arizona
$198 -$12.1K -88,000 -98%
TRCT
44
Tower Research Capital (TRC)
New York
$91 -$1.4K -10,221 -94%
WSFS
45
Wilmington Savings Fund Society
Delaware
$79 – – –
HWM
46
HighMark Wealth Management
Minnesota
$37 – – –
PA
47
Parallel Advisors
California
$33 – – –
BNP Paribas Financial Markets
48
BNP Paribas Financial Markets
France
$28 – – –
ASN
49
Advisory Services Network
Georgia
$16 +$17 +125 New
IRC
50
Investors Research Corp
Georgia
$13 – – –
1
2
3 4

ADAP Hedge Fund Activity: Q3 2025 in Review

55 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q3 2025, worth a combined $5.47M — down 80% from $27.7M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of ADAP and 14 opened new positions — a net loss of 10 holders — while 12 trimmed existing stakes and 7 added.

The largest buyer was UBS Group, adding an estimated $906K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $6.57M sold.

  • 55 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q3 2025, down from 65 in Q2 2025.
  • Funds reported $5.47M of Adaptimmune Therapeutics stock for Q3 2025, down 80% quarter-over-quarter.
  • 14 funds opened new Adaptimmune Therapeutics positions in Q3 2025 and 24 closed out, a net change of -10 holders.
  • The largest Adaptimmune Therapeutics buyer in Q3 2025 was UBS Group, an estimated $906K added.
  • The largest Adaptimmune Therapeutics seller in Q3 2025 was EcoR1 Capital, an estimated $6.57M sold.

Based on aggregated 13F filings for Q3 2025.